Global Leading Market Research Publisher QYResearch announces the release of its latest report “Automated Whole-Breast Ultrasound (ABUS) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Automated Whole-Breast Ultrasound (ABUS) market, including market size, share, demand, industry development status, and forecasts for the next few years.
The Automated Whole-Breast Ultrasound (ABUS) market represents a rapidly advancing segment within the global medical imaging and women’s health diagnostics industry. As healthcare systems worldwide intensify efforts in early breast cancer detection and precision screening, ABUS technology is emerging as a transformative complementary imaging modality alongside mammography. Its ability to generate high-resolution 3D volumetric images of the entire breast makes it particularly valuable for patients with dense breast tissue, where traditional mammography often shows limited sensitivity.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6115559/automated-whole-breast-ultrasound–abus
From a market size perspective, the global Automated Whole-Breast Ultrasound (ABUS) market was valued at approximately US$ 974 million in 2025 and is projected to reach US$ 1,825 million by 2032, expanding at a robust CAGR of 9.5% during the forecast period of 2026–2032. This strong growth trajectory is primarily driven by increasing global breast cancer incidence rates, rising awareness of early screening programs, and expanding investments in advanced diagnostic imaging infrastructure across both developed and emerging healthcare systems.
In terms of product definition, Automated Whole-Breast Ultrasound (ABUS) is an advanced medical imaging system that utilizes high-frequency ultrasound waves to automatically scan and reconstruct the entire breast into detailed three-dimensional images. Unlike conventional handheld ultrasound, ABUS provides standardized, reproducible, and operator-independent imaging results, significantly improving diagnostic consistency. It is primarily used as an adjunct screening tool to mammography, especially for women with dense breast tissue, where tumor detection accuracy can be challenging.
The technological foundation of ABUS systems lies in the integration of ultrasonic transducers, imaging probes, acoustic coupling materials, advanced electronic circuit modules, and increasingly, AI-powered image interpretation software. These components work together to enable high-resolution image acquisition, automated scanning workflows, and enhanced lesion detection capabilities. The industry’s gross profit margin typically ranges between 38% and 45%, reflecting the high-value nature of medical imaging equipment and the strong contribution of proprietary software and algorithm integration.
In 2024, global production of ABUS systems reached approximately 6,800 units, with an average global selling price of around US$ 220,000 per unit. This indicates a capital-intensive but highly specialized market structure, where each unit represents a high-value clinical investment for hospitals and diagnostic centers. The market is characterized by relatively low volume but high technological intensity, with procurement decisions heavily influenced by clinical performance, regulatory approvals, and long-term service support capabilities.
The ABUS industry value chain is highly technology-driven and vertically integrated. The upstream segment includes critical components such as ultrasonic transducers, imaging probes, acoustic gels, precision electronic modules, and AI-based diagnostic software algorithms. These upstream technologies directly determine imaging resolution, scanning speed, and diagnostic accuracy. Midstream activities focus on system integration, including complete machine assembly, imaging system calibration, software-hardware synchronization, and user interface development for clinical workflows. Downstream demand is concentrated in hospitals, breast cancer screening centers, maternal and child health institutions, and general physical examination facilities.
From a competitive landscape perspective, the ABUS market is dominated by a mix of global medical imaging leaders and specialized medical technology innovators. Key players include GE HealthCare, Siemens Healthineers, Canon Medical Systems Corporation, Hitachi Healthcare (Fujifilm Group), SonoCiné Inc., Seno Medical Instruments, QT Imaging Inc., Delphinus Medical Technologies, Zoncare, and Mindray.
Global leaders such as GE HealthCare, Siemens Healthineers, Canon Medical Systems, and Fujifilm (Hitachi Healthcare) maintain strong competitive advantages through extensive R&D capabilities, global distribution networks, and established relationships with major hospital systems. These companies are actively integrating AI-driven diagnostic tools, cloud-based imaging platforms, and workflow automation technologies to enhance clinical efficiency and diagnostic accuracy. Meanwhile, emerging innovators such as QT Imaging and Delphinus Medical Technologies are focusing on next-generation ultrasound architectures and advanced breast imaging modalities, contributing to technological diversification within the sector.
In terms of segmentation, the market is divided into semi-automatic and fully automatic ABUS systems. Fully automatic systems are gaining increasing traction due to their higher operational efficiency, reduced dependence on operator skill, and improved reproducibility of imaging results. Semi-automatic systems continue to serve cost-sensitive markets and smaller clinical settings where budget constraints remain a key purchasing factor.
Application-wise, hospitals represent the dominant end-use segment, driven by high patient throughput, integrated diagnostic departments, and strong procurement capacity. Clinics and specialized diagnostic centers are also expanding their adoption of ABUS systems, particularly in regions with growing awareness of early breast cancer screening programs. Other institutional users, including preventive health centers and research institutions, contribute to niche but growing demand.
The industry is currently undergoing several structural transformations. First, artificial intelligence integration is becoming a central competitive differentiator, enabling automated lesion detection, image enhancement, and diagnostic decision support. Second, there is a strong shift toward standardized, operator-independent imaging systems, which improve reproducibility and reduce diagnostic variability. Third, healthcare infrastructure expansion in emerging economies is significantly broadening the addressable market for advanced breast imaging technologies.
In addition, government-led cancer screening initiatives and public health policies promoting early detection are playing a critical role in market expansion. According to healthcare policy directions observed in multiple regions, breast cancer screening is increasingly being integrated into national preventive healthcare frameworks, further supporting ABUS adoption in large-scale screening programs.
Looking forward, the Automated Whole-Breast Ultrasound market is expected to maintain strong and sustained growth momentum, driven by technological innovation, rising clinical demand for early cancer detection, and continued expansion of healthcare infrastructure. Companies that successfully integrate imaging hardware excellence with AI-powered diagnostic ecosystems are expected to lead the next phase of industry evolution.
Overall, ABUS is transitioning from a supplementary imaging tool into a core component of modern breast cancer screening pathways, representing a high-growth, innovation-intensive segment within global medical imaging.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
